Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Holdings Lifted by Barclays PLC

Barclays PLC increased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 145.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 79,740 shares of the company's stock after purchasing an additional 47,239 shares during the period. Barclays PLC owned 0.15% of Stoke Therapeutics worth $980,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of STOK. Quest Partners LLC acquired a new position in shares of Stoke Therapeutics in the 2nd quarter worth approximately $29,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stoke Therapeutics in the second quarter worth $123,000. Intech Investment Management LLC bought a new stake in Stoke Therapeutics during the third quarter valued at $160,000. The Manufacturers Life Insurance Company raised its holdings in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock worth $189,000 after purchasing an additional 1,994 shares during the period. Finally, Profund Advisors LLC bought a new position in shares of Stoke Therapeutics in the 2nd quarter worth about $201,000.

Stoke Therapeutics Trading Up 2.1 %

STOK stock traded up $0.23 during trading on Tuesday, hitting $11.03. The company had a trading volume of 206,963 shares, compared to its average volume of 745,045. The business has a 50 day moving average of $12.25 and a 200 day moving average of $13.28. The firm has a market capitalization of $584.23 million, a price-to-earnings ratio of -5.25 and a beta of 0.95. Stoke Therapeutics, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, equities analysts predict that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Edward M. Md Kaye sold 6,786 shares of the company's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $88,150.14. Following the completion of the sale, the chief executive officer now owns 61,885 shares in the company, valued at $803,886.15. This represents a 9.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Barry Ticho sold 13,945 shares of the firm's stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $178,217.10. Following the transaction, the insider now directly owns 47,332 shares of the company's stock, valued at $604,902.96. This represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock worth $809,421 over the last ninety days. Company insiders own 11.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on STOK shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partners initiated coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an "outperform" rating and a $18.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partnrs upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. Finally, Chardan Capital initiated coverage on Stoke Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating and a $24.00 target price on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $21.29.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.